ONCAlert | Upfront Therapy for mRCC

The IMpassion130 trial in Metastatic Triple-Negative Breast Cancer

Rita Nanda, MD
Published Online: 1:12 AM, Thu December 12, 2019

Rita Nanda, MD, associate professor of medicine and director of the Breast Oncology Program at The University of Chicago, discusses the IMpassion130 trial in patients with metastatic triple-negative breast cancer (TNBC) who express PD-L1.

The IMpassion130 trial has been practice-changing for Nanda and many other providers, creating a new standard of care for women with metastatic TNBC whose cancer expresses the PD-L1 protein. Pembrolizumab is not yet approved in the neoadjuvant setting, but Nanda is hopeful it will come.

The follow-up data of the IMpassion130 trial for event-free survival is not yet significant but there is a favorable trend to improvement in event-free survival as well as a pathological complete response for women who receive pembrolizumab in conjunction with neoadjuvant chemotherapy. That benefit was seen regardless of PD-L1 status. Updated results of the IMpassion130 trial will be announced at the 2019 SABCS Annual Meeting.

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.